Medicines manufacturer and supplier Morningside Pharmaceuticals has appointed a new Chief Executive Officer (CEO) and Chairman to oversee the company’s governance.
The Executive team and Group Board will be responsible for enhancing internal and external systems and processes, as well as delivering the business’ ambitious growth plans for the future.
As part of the structure changes the company’s Founder and Chief Executive for almost 30 years, Dr Nik Kotecha OBE, has taken on a key strategic role for the business and become Chairman of the Board.
Tim Brady, who has extensive experience of leading Business Development and Sales & Marketing in the pharmaceuticals’ sector, has become the business’ new CEO. Tim joins newly appointed Chief Operating Officer (COO) Monica Huang and Chief Financial Officer (CFO) Cliff Fung, as leader of the company’s Executive team.
Morningside’s Chairman of the Board Dr Nik Kotecha OBE said: “Morningside was founded in the 1990s through an entrepreneur’s dream of making quality healthcare an affordable and accessible reality throughout the world.
“Since then we have grown from a garage start-up to one of the Midlands’ leading life sciences businesses. None of this would have been possible without our excellent people, past and present, who have made Morningside the highly successful business it is today.
“The appointment of the Executive team is a key part of our strategic plans for continuing to grow Morningside into the future. For my part, I am very much looking forward to becoming Chairman of the Board which will play a key strategic role in guiding the business’ strategy, alongside the new Executive team.
“My passion is entrepreneurship and helping businesses grow through investing in innovation, Research & Development and exporting to international markets. To help support these core areas I will continue to take on senior regional and national advisory roles. I am also immensely proud to have founded the Randal Charitable Foundation in 2017, which has an unwavering vision to save lives, help the socially disadvantaged and significantly improve the quality of life for those in need in the UK and around the world. My focus will continue to be Morningside as well as supporting these key business, community and philanthropic endeavours.”
“I would very much like to welcome Tim to Morningside, who will take the helm during this exciting new chapter in our company’s history.”
Morningside’s growth plans include launching new niche generic medicines from its Research & Development (R&D) pipeline, registering products in international territories and further growing our branded and generic medicines portfolio and market share in the UK.
The business is a leading manufacturer and supplier of quality generic and branded medicines to the United Kingdom and export markets, which includes twice daily deliveries to the NHS, hospitals and pharmacies in the UK; and supplying vital medicines and healthcare products to charities, Non-Governmental Organisations (NGOs) and International Aid Agencies world-wide.
Introducing Tim Brady
Tim Brady joins Morningside as the business’ new Chief Executive. He has over 30 years’ experience of working in senior roles in the pharmaceuticals sector. His career has led to him building a successful pharma business from the ground up, to being a country and European executive for global life sciences businesses. More recently Tim has taken on a number of senior directorships, specialising in the areas of Business Development, Sales & Marketing, as well as International Sales.
Mr Brady, said: “Morningside is built on very solid foundations and is set for an even faster period of growth. The Leadership Team at Morningside is the best in the industry; they have proven that over the past 30 years and the challenge now is to get even better at what we do.
“All the people at Morningside are fully engaged, motivated, knowledgeable and excited about the future and this will be a hugely important advantage for us as we continue to build our reputation as a key supplier to the NHS and international markets.
“Morningside has always had an enviable product pipeline, which is going to produce some important new products in the coming months and years. An even sharper focus on speed to market for these products and stronger relations with our customers and supply chain, will mean patients and doctors will have greater choice of medicines, more quickly.”
Tim Brady started his new role at the beginning of September 2020.